scholarly journals Correlation between the −1562C/T polymorphism in the matrix metalloproteinase-9 gene and hemorrhagic transformation of ischemic stroke

2015 ◽  
Vol 9 (3) ◽  
pp. 1043-1047 ◽  
Author(s):  
XIAOMAN ZHANG ◽  
XINHUI CAO ◽  
XIAOYU XU ◽  
AIFAN LI ◽  
YUMING XU
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Hemorrhagic Transformation ◽  
Matrix Metalloproteinase 9 ◽  
The Matrix ◽  
Metalloproteinase 9

Influence of the Matrix Metalloproteinase 9 Geners3918242 Polymorphism on Development of Ischemic Stroke: A Meta-analysis

2020 ◽  
Vol 133 ◽  
pp. e31-e61 ◽  
Author(s):  
Guangliang Wu ◽  
Haiyan Cai ◽  
Guoming Li ◽  
Shuhui Meng ◽  
Jingyan Huang ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Meta Analysis ◽  
Matrix Metalloproteinase 9 ◽  
The Matrix ◽  
Metalloproteinase 9

Abstract TMP22: Intravenous Glyburide Treatment is Associated with Reduced Matrix Metalloproteinase-9 in Human Acute Stroke

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Ly Pham ◽  
Sydney O’Connor ◽  
Karen Yarbrough ◽  
Sven Jacobson ◽  
Barney J Stern ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Matrix Metalloproteinase ◽  
Active Form ◽  
Pilot Trial ◽  
Specific Inhibitor ◽  
Matrix Metalloproteinase 9 ◽  
Stroke Patients ◽  
Hemispheric Stroke ◽  
Intravenous Tissue Plasminogen Activator ◽  
Metalloproteinase 9

Background: Elevated matrix metalloproteinase-9 (MMP-9) following acute ischemic stroke is associated with blood-brain barrier breakdown and hemorrhagic conversion. Prior retrospective evidence suggests that sulfonylurea use may be associated with reduced risk of hemorrhagic conversion. We hypothesized that sulfonylureas may reduce MMP-9 level in stroke patients. Methods: Using serial plasma samples from six subjects in the Glyburide Advantage in Malignant Edema and Stroke Pilot trial (GAMES-Pilot), we evaluated the level of MMP-9 in human subjects presenting with large hemispheric stroke who were treated with intravenous glyburide (RP-1127). MMP-9 was measured in a control cohort with large ischemic stroke who were not treated with glyburide. Commercially available ELISA kits and gel zymography were used to measure MMP-9 at baseline and at approximately 48 hours after stroke. GAMES subjects had additional time points analyzed until approximately 84 hours after stroke. Results: Average MMP-9 level in glyburide-treated stroke patients was 47.2 ± 8.0 ng/mL compared to 143.4 ± 60.35 ng/mL in untreated control subjects (p=0.004). Zymography analysis demonstrated a significant decrease in the pro-enzyme but no change in the active form of MMP-9. There was no difference in the level of the MMP-9 specific inhibitor, TIMP-1. No subjects exhibited parenchymal hemorrhagic conversion on 24 hour head CT scan. Conclusions: Glyburide treatment in human stroke patients with large hemispheric stroke is associated reduced level of MMP-9. Elucidating the underlying mechanism of glyburide’s effect on MMP-9 and the risk of hemorrhagic conversion may highlight future directions of therapy, including in combination with intravenous tissue plasminogen activator (IV t-PA).

Sign in / Sign up

Export Citation Format

Share Document